Locoid is a drug owned by Bausch Health Americas Inc. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2026. Details of Locoid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7378405 | Stabilized steroid composition and method for its preparation |
Dec, 2026
(2 years from now) | Active |
| US7981877 | Stabilized steroid composition and method for its preparation |
Jan, 2025
(2 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Locoid's patents.
Latest Legal Activities on Locoid's Patents
Given below is the list of recent legal activities going on the following patents of Locoid.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Dec, 2022 | US7981877 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2019 | US7981877 |
| Expire Patent Critical | 24 Jun, 2016 | US7378405 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 08 Jan, 2015 | US7981877 |
| Email Notification Critical | 31 Oct, 2012 | US7981877 |
| Change in Power of Attorney (May Include Associate POA) Critical | 31 Oct, 2012 | US7981877 |
| Correspondence Address Change Critical | 30 Oct, 2012 | US7981877 |
| Email Notification Critical | 24 Oct, 2012 | US7378405 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Oct, 2012 | US7378405 |
| Post Issue Communication - Certificate of Correction | 23 Oct, 2012 | US7981877 |
US patents provide insights into the exclusivity only within the United States, but Locoid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Locoid's family patents as well as insights into ongoing legal events on those patents.
Locoid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Locoid's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Locoid Generic API suppliers:
Hydrocortisone Butyrate is the generic name for the brand Locoid. 6 different companies have already filed for the generic of Locoid, with Taro Pharm Inds having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Locoid's generic
How can I launch a generic of Locoid before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Locoid's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Locoid's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Locoid -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.001 | 31 Aug, 2016 | 1 | 21 Nov, 2017 | 19 Dec, 2026 | Eligible |
Alternative Brands for Locoid
There are several other brand drugs using the same active ingredient (Hydrocortisone Butyrate) as Locoid. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Precision Dermat |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydrocortisone Butyrate, Locoid's active ingredient. Check the complete list of approved generic manufacturers for Locoid
About Locoid
Locoid is a drug owned by Bausch Health Americas Inc. Locoid uses Hydrocortisone Butyrate as an active ingredient. Locoid was launched by Bausch in 2007.
Approval Date:
Locoid was approved by FDA for market use on 18 May, 2007.
Active Ingredient:
Locoid uses Hydrocortisone Butyrate as the active ingredient. Check out other Drugs and Companies using Hydrocortisone Butyrate ingredient
Dosage:
Locoid is available in lotion form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | LOTION | Discontinued | TOPICAL |